NEW YORK, March 12 (Reuters) - A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson of providing drug pricing tools to doctors to induce them to purchase drugs from the company.
The decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restores claims by Adam Hart, a former McKesson business development executive. (Reporting by Jonathan Stempel in New York)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
These proven wealth builders could be exactly what you're searching for right now.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
The JPMorgan Nasdaq Equity Premium Income ETF offers a compelling blend of income and upside to my portfolio.
Here's what could happen next to Microsoft shares.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
Nvidia and Super Micro Computer have been the best-performing S&P 500 stocks of 2024, but select Wall Street analysts still see substantial upside for shareholders.
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.